申请人:Pfizer Limited
公开号:EP0200524A2
公开(公告)日:1986-11-05
Dihydropyridine calcium antagonists, useful in the treatment of conditions such as angina and hypertension, of the formula:-
where
R is an optionally substituted aryl or heteroaryl group;
R' and R2 are each independently selected from
i) C1-C4 alkyl and
ii) C1-C4 alkyl substituted by C3-C7 cycloalkyl, aryl, CF3, C2-C4 alkanoyl, halo, hydroxy, C1-C4 alkoxy, C2-C4 alkanoyloxy, aryl-(C1-C4 alkoxy). or - NR4R5;
m is 0, 1 or 2;
R3 is H, C1-C4 alkyl or -COCF3;
R4 is H or C1-C4 alkyl;
R5 is H, C1-C4 alkyl or aryl-(C1-C4 alkyl); and
Y is (CH2), where n is 2,3 or 4. CH2CH(CH3) - or
and their pharmaceutically acceptable salts.
二氢吡啶类钙拮抗剂,可用于治疗心绞痛和高血压等病症,其式如下: - 式中
式中
R 是任选取代的芳基或杂芳基;
R' 和 R2 各自独立选自
i) C1-C4 烷基和
ii) 被 C3-C7 环烷基、芳基、CF3、C2-C4 烷酰基、卤代、羟基、C1-C4 烷氧基、C2-C4 烷酰氧基、芳基-(C1-C4 烷氧基) 或 - NR4R5 取代的 C1-C4 烷基;
m 是 0、1 或 2;
R3 是 H、C1-C4 烷基或-COCF3;
R4 是 H 或 C1-C4 烷基;
R5 是 H、C1-C4 烷基或芳基-(C1-C4 烷基);以及
Y 是 (CH2),其中 n 是 2、3 或 4。CH2CH(CH3) - 或
及其药学上可接受的盐类。